A photo shows the company’s logo on the headquarters of Danish biotechnology company Bavarian Nordic in Hellerup, north of Copenhagen.
Liselotte Sabroe | Afp | Getty Images
Shares of Danish biotech company Bavarian Nordic jumped more than 12% in early deals on Thursday after it reported stronger-than-expected earnings and announced a bumper vaccine order from an unnamed European country amid the ongoing mpox outbreak.
Bavarian Nordic reported second quarter revenues of 1.43 billion Danish krone ($213 million) and operating profit of 420 million krone, ahead of analyst expectations cited by Reuters.
Shares were up 12.5% by 9:24 a.m. London time.
In a statement on Wednesday, the firm also said it had received a 440,000 dose contract to supply mpox and smallpox vaccines to an undisclosed European country.
The order comes after the World Health Organization last week declared mpox a global public health emergency following the spread of an outbreak in the Democratic Republic of Congo (DRC) to neighboring countries.
This is a breaking news story. Please check back for updates.